Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia

CONTEXT: The safety and efficacy of feminizing hormone therapy in aging transgender (trans) individuals is unclear. Current recommendations suggest transdermal estradiol beyond the age of 45 years, especially if cardiometabolic risk factors are present. OBJECTIVE: To evaluate feminizing hormone ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Balcerek, Matthew I., Nolan, Brendan J., Brownhill, Adam, Wong, Peggy, Locke, Peter, Zajac, Jeffrey D., Cheung, Ada S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313995/
https://www.ncbi.nlm.nih.gov/pubmed/34326812
http://dx.doi.org/10.3389/fendo.2021.667403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313995/
https://www.ncbi.nlm.nih.gov/pubmed/34326812
http://dx.doi.org/10.3389/fendo.2021.667403

Ejemplares similares